JAWAHARLAL NEHRU
MEDICAL COLLEGE,
BELAGAVI
IR17-MEDI-2-1-N002
MEDICAL
Parameter
2D.FPPP
S.No. Financial YearName of faculty
(Chief Consultant)
Client
Organization
Title of Consultancy of
project
Amount
received
(in Rupees)
Amount
received
(in words)
1 2015-16
Dr. Rajesh Powar, Dr. K.M. Keluskar, Dr. Kotrashetti
Department of
Plastic Surgery, Pediatric Surgery, Oral and Maxillofacial Surgery, Orthodontics and DentofacialOrthopaedics
Smile Train, USA 1. KLE’S Smile Train project
69,00,000/- Sixty Nine Lakh only
Consultancy Projects
Institute Name
India Ranking 2017
ID
Discipline
Dr. B.S. Kodkany Dr. S.S. Goudar,
Dr. N.S. MahantshettiDr. M.B. BelladDr. R.M. BelladDr. S.M. DhadedDr. YeshitaPujarDr. HemaDhumaleDr. M.c. Metgud
Dept. of Paediatrics, ObG, Physiology, Community Medicne of J.N. Medical College, Belagavi
• NIH, USA• NICHD, USA
• Global Implementation Task Force of American Academy of Pediatrics, USA• Bill and
Melinda Gate’s Foundation, USA• WHO,• Thrasher Research Fund, USA• International Atomic Energy
Agency, Vienna• RHR Division of World Health Organization, Geneva, Switzerland• University of Colorado Health
Sciences Center• The Children
• Research on Women and child Health
• Maternal and Newborn Health Registry (MNH Registry)Dept. of OBG & Paediatrics• Helping babies breathe initiative Dept. of Paediatrics
• The CLIP (Community Level Interventions for Pre- Eclampsia) Cluster randomized controlled trial• Dept. of OBG • Does Implementation of Helping Babies Breathe
(HBB) save lives?• Dept. of Paediatrics• Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries (ACT) in Belagavi District,
Karnataka, India• Dept. of OBG &
21,88,000/- Twenty one lakhs eighty
eight thousand
Dr. M.V, JaliDr. R.S. Mudhol
KLE Dr. Prabhakar Kore Hospital & MRC, Belagavi
Govt. of Karnataka Insurance companies
2. Yashaswini, 3. Balasanjivini, 4. Arogya Bhagya, 5. Vajapayee Arogyashree Scheme, 6. Ex-servicemen
Contributory Health Scheme (ECHS),7. Employe’s State
Insurance (ESI), DBCS
6,18,91,767/- Six crore eighteen lakh ninety one thousand seven hundred and sixty seven
Dr .V. A. Kothiwale - PI
Dr.Aditya.Kulkarni–Sub-I Dr. M S Ganachari-CRCBhupendra Parihar- CRCDisha Khoda- CRC
Norwich 8. Protocol title: “A proof of concept, parallel
design, single treatment, double arm trial of 50 mg quick dissolve tablets containing freeze dried Lactobacillus delbrueckii subsp. bulgaricus lysate (GenCixTM) from FraXon
technologies Inc., USA, conducted on treatment naïve chronic hepatitis C positive patients in one arm and treatment naïve chronic hepatitis C positive patients on dialysis in the other arm”
40,000/- Forty thousand
Dr. Gajanan.S.Gaude– PI Dr.V.A.Kothiwale
–Sub-I
Glenmark 9.Protocol Number: GPL-CT/2011l011/lII“A Phase
III, randomized, open label, Non- inferiority, active-controlled comparative, parallel group, multicentric study of fixed dose combination of formoterol 12 μg plus
fluticasone 250 μg as DPI (Test Drug) with the commercially available fixed dose combination of Salmeterol 50μg and Fluticasone250 μg
(SeretideTMAccuhalerTM
50/250 μg) as DPI in a 12-
week Treatment period of adolescent and adult subjects with moderate-severe stable persistent asthma”
40,000/- Forty thousand
Glenmark 10.Protocol title - C003 –“A double blind,
randomized, placebocontrolled, parallel group,three arm, multicenterand multinational pivotalstudy to assess theefficacy and safety of twodosage regimens of
Crofelemer tablets in thetreatment of moderate tosevere acute waterydiarrhea in adultpatients.”
40,000/- Forty thousand
Dr.N.S.Mahantshetti-PI Dr.
Joshi- Sub-I
Bharat Biotech 11.Protocol title -“A phase II/III randomized, single
blinded, active controlled study to evaluate the immunogenicity and safety of inactivated Japanese encephalitis vaccine in healthy volunteers”.
50,000/- Fifty thousand
Dr. V.D.Patil - PI Dr.Preeti Amarkhed-Sub
I Dr.M S Ganachari- CRC
Biological E. Limited
12. Trial no: BECT/JEV-PII-III/018, Protocol no:
bect018/jev-pii-iii/ctp-02 “A multicentric, open label randomized controlled phase ii/iii study to evaluate the safety and immunogenicity of be’s
inactivated je vaccine in healthy ≥ 1 to <3 year old Indian children”
45,000/- Forty five thousand
Panacea 13. Protocol number: PBL/CR/0032008/CT “A randomized, multicenter, open
label, comparative study to evaluate the Immunogenicity and reactogenicity of a new fully liquidpentavalentDTwP-Hib-IPV vaccine
EasyfourPol™ , Panacea Biotec Ltd) with tetravalent DTwP/Hib vaccine (TetrAct-Hib™) , co-administered with Imovax Polio® (Salk Based Inactivated Polio
Vaccine) of Sanofi Pasteur India Pvt. Ltd. In healthy infants.
40,000/- Forty thousand
Reliance 14. Protocol number :RLS/TP/2010/03:“Prosp
ective, multicentric, open label, clinical study to evaluate efficacy and safety of R-TPR-004 in patients undergoing treatment for acute ischemic stroke”
25,000/- Twenty five thousand
Quintile
15.Protocol number: DU176b-C-U305: “A phase 3, randomized, double-blind, double-dummy, parallel-group,
multi-center, multi-national study for the evaluation of efficacy and safety of (lmw) heparin/edoxaban versus (LMW) Heparin/Warfarin in subjects with
symptomatic deep-vein thrombosis and/or pulmonary embolism”
30,000/- Thirty thousand
George Institute 16. Protocol number BC22140 ALEGLITAZAR
(RO0728804): “Phase 3 multicenter, randomized, double-blind, parallel group, placebo controlled study cardiovascular outcomes study to evaluate the potential of
aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ASC) event and type 2 diabetes mellitus (T2D)”
20,000/- Twenty thousand
Dr. M. Khanpet –PIDr. VinayakEkbot – Sub IDr. M SGanachari - CRC
Clinigene, International Ltd
17. Protocol title: “A phase II, randomized, open label, single subcutaneous dose study
30,000/- Thirty thousand
Quintile 18.Protocol number:DU176b-C-U301: “A Phase3, randomised, double-
blind, double dummy,parallel group, multi-
35,000/- Thirty five thousand
GlaxoSmithKline 19. Protocol title: “A phase III, open-label, randomized, multicenter study to evaluate the immunogenicity and
30,000/- Thirty thousand
Dr .V. A. Kothiwale –PI Dr.
M. S. Ganachari -CRCKhoremand Bhathena-CRC Atul.Aggrawal-CRC
Thrombosis Research
Institute
20Protocol number TRI08888
GARFIELD:“Prospective, multicentre, international registry of male and female patients newly diagnosed with atrial fibrillation”.
50,000/- Fifty thousand
SHAN Pharmaceuticals
21Protocol StudyNumber: SH501:“Safety,immune lot-to-lotconsistency and non-inferiority of Shan 5(DTwP-HepB-Hib)
vaccine in comparison topentavac SD whenadministered as a singlebooster dose at 15-18months and three dose at6-8,10-12 and 14-16weeks of age in healthyindian children and
infants”
30,000/- Thirty thousand
Glenmark 22.Protocol number:GPL/CT/2012/III: “Arandomised, double-blind,comparative, prospective,multicentre, parallel study
to assess efficacy, safetyand tolerability ofRepaglidine/Metformin IR tablet monotherapy orrepaglidine tabletmonotherapy in adult
35,000/- Thirty five thousand
Dr. M.V. Jali –PI ICON Clinical Research-
Company
23.Protocol number: CV181169 :A multicentre,
randomised, double-blind, active-controlled, parallel group, phase 3 trial to evaluate the safety of add-on therapy with Saxagliptin and Dapagliflozin added to
Metformin compared to add-on therapy with Saxagliptin in combination with Metformin or Dapagliflozin in combination with Metformin in Subjects
with type 2 Diabetes who have inadequate glycemic control on Metformin alone.”
45,000/- Forty five thousand
Glenmark 24. Protocol number:
GRC17536-203: “A Phase2, 4-week randomized,double-blind, parallelgroup, placebo controlledproof of concept study toevaluate efficacy, safetyand tolerability of grc17536 in patients with
painful diabeticperipheral neuropathy.”
30,000/- Thirty
thousand
Dr. M.V. Jali –PI Piramal Healthcare
25.Protocol number: P2202/47/10: “A Phase II,
randomized, double-blind, placebo-controlled, dose-ranging, two-staged, fixed design study to evaluate the efficacy, safety, tolerability and pharmacokinetics of
p2202 in overweight/obese patients of type 2 diabetes mellitus inadequately controlled on metformin, sulphonyl urea, or both.”
50,000/- Fifty thousand
Dr .V. A. Kothiwale -PI Dr. MS Ganachari- CRCTarang Shah - CRC
Amgen Technology Pvt.ltd
26.Protocol no: 20110118:“A double-blind, randomized, placebo-controlled, multicenter study assessing the impact of
additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease”.
30,000/- Thirty thousand
Glenmark 27.Study title: “A Phase III prospective, randomized,
open labelled, multicentric, parallel group, three arms clinical study to evaluate the efficacy and safety between monotherapy of Glenmark’sRoflumilast
500 Mcg Tablet and Combination Therapy of Roflumilast 500 Mcg Tablet Plus Tiotropium 9 mcg inhalation and combination therapy of roflumilast 500 mcg tablet plus salmeterol 25mcg
inhalation in adult patients with chronic obstructive pulmonary disease (COPD).”
25,000/- Twenty five thousand
Serum Institute 28.Protocol title: “A multicentricrandomized ,
comparative clinical trial to assess the immunogenicity and reactogenicity of DPTw [meat free] vaccine with standard commercially available DPTw [routine]
vaccine in Indian children aged 6 –14 weeks”.
40,000/- Forty thousand
Reliance 29.Protocol title: To studythe safety and efficacy ofR-TPR –001 (Reteplase-Recombinant
plasminogen activator) inpatients with acutemyocardial infarction andST segment elevation”.
20,000/- Twenty thousand
Novonordisk 30.Protocol title: EX 1000-1919: A multicentre,
multinational, randomized, open labeled, two armed, parallel group trial with a 24 week treatment period comparing the efficacy and safety of two
concentrations of Mixtard 30 (333IU/mL) or Mixtard 30 (1000IU/mL)”.
20,000/- Twenty thousand
SMO India. 31.Protocol title: A Phase
III , multicenter,randomized , double –blind study to evaluatethe efficacy and safety ofsitagliptin versus glipizide
in patients with type 2diabetes mellitus and
chronic renal insufficiency who have inadequateglycemic control”
30,000/- Thirty
thousand
Medical director Medical Superintendent
Govt. of Karnataka
Balasanjeevini Vajapayee Arogya Scheme
2,00,25,342 Two crore twenty five thousand three
hundred forty two
2 2014-15
13 Dr.Rajesh Powar · Smile Train,USA
1. KLE,S Smile Train project
71,59,000/- Seventy One Lakh Fifty Nine
Thousand only/-
14 · NIH, USA · NICHD,
USA Global Implementation Task Force of American Academy of Pediatrics,
USA Bill and Melinda Gate’s Foundation, USA WHO, Thrasher
Research Fund, USA International Atomic Energy Agency, Vienna • RHR
Division of World Health
2. Research on Women and child Health
3. Maternal and Newborn Health Registry (MNH Registry)Dept. of OBG & Paediatrics4. Helping babies breathe initiative Dept. of Paediatrics
5. The CLIP (Community Level Interventions for Pre- Eclampsia) Cluster randomized controlled trialDept. of OBG 6. Does Implementation of Helping Babies Breathe (HBB) save lives?Dept. of
Paediatrics7. Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries (ACT) in Belagavi District, Karnataka, IndiaDept. of
OBG & Paediatrics8. Emergency obstetrics
20,82,000/- Twenty lakhs eighty two
thousand
15 15. Govt. of Karnataka Insurance companies
• Yashaswini, • Balasanjivini, • Arogya Bhagya, • Vajapayee Arogyashree Scheme, • Ex-servicemen
Contributory Health Scheme (ECHS), • Employe’s State
Insurance (ESI), DBCS
5,09,72,744/- Five crore nine lakh seventy two thousand seven hundred and forty four
Dr.(Mrs)N.S.Mahantshetti -PI
18.Biological E. Limited –
Company
18. Protocol title: A Multicentric double blind
single arm randomized phase IV study to evaluate the safety, reactogenicity and lot consistency of three production lots of BE’s combined liquid Pentavalent DTwP-rHepB-
HIB vaccine administered at 6-10-14 weeks schedule to 6-8 week old healthy Indian infants.
75,000/- Seventy thousand
19.SMO India – CRO
19. Protocol no: GLP114130: “A randomized, double-blind, active-controlled, parallel group, multicenter study to determine the efficacy and safety of Albiglutide as compared with
Sitagliptin in subjects with type 2 Diabetes mellitus with renal impairment”
80,000/- Eighty thousand
20.Abbott 20 Protocol title: A prospective multicenter
observational study to characterize the patient population with cholestasis in chronic liver disease due to non-alcoholic liver disease receiving heptral in
India[P13-163]
70,000/- Seventy thousand
21. Panacea Biotec Ltd
21.Protocol number: PBL/CR/0032008/CT “A randomized, multicenter, open label, comparative study to evaluate the immunogenicity and
reactogenicity of a new fully liquid Pentavalent DTwP-Hib-IPV vaccine (easyfourPol™,) with tetravalent DTwP/Hib vaccine (TetrAct-Hib™), co-administered with
Imovax Polio® (Salk Based Inactivated Polio Vaccine) of Sanofi Pasteur India Pvt. Ltd. In Healthy Infants.
1,00,000/- One lakh
22.ICON 22. Protocol no: MB102073: “A
multicenter, randomized, double-blind, placebo-controlled, parallel group, phase iii trial to evaluate the safety and efficacy of dapagliflozin in subjects with type 2 Diabetes with
inadequately controlled Hypertension on an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker”.
50,000/- Fifty thousand
23 23. Protocol no: MB102077: “A
multicentre, randomized, double-blind, placebo-controlled, parallel group, phase III trial to evaluate the safety and efficacy of Dapagliflozin in subjects with type @ Diabetes with
inadequately controlled hypertension treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and an additional antihypertensive
medication”.
40,000/- Fortythousand
24.Clinigene International Ltd
24. Protocol number: MK-0822: “Phase III
randomized, placebo–controlled clinical trial toassess the safety andefficacy of Odanacatib(mk-0822) to reduce therisk of fracture inosteoporotic post
menopausal womentreated with vitamin Dand calcium”.
50,000/- Fifty thousand
Dr. V.D.Patil - PIDr. Preeti Amarkhed-
Sub IDr.M S Ganachari – CRC
25. Biological E. Limited -
Company
25. Trial no: BECT/JEV-PII-III/018, Protocol no:
bect018/jev-pii-iii/ctp-02 “A multicentric, openlabel randomizedcontrolled phase II/IIIstudy to evaluate thesafety andimmunogenicity of be’s
inactivated JEvaccine in healthy ≥ 1 to<3 year old Indianchildren”
70,000/- Seventy thousand
Medical director Medical Superintendent
Govt. of Karnataka
Balasanjeevini Vajapayee Arogya Scheme
1,61,61,443 One crore Sixty one lakhs sixty one thousand four hundred forty three
3 2013-14Dr.Rajesh. Power · Smile train
USA1. KLE’S Smile Train project
69,12,000/- Sixty Nine Lakh Twelve thousand Only
• NIH, USA• NICHD, USA
• Global Implementation Task Force of American Academy of Pediatrics, USA• Bill and Melinda Gate’s
Foundation, USA• WHO,• Thrasher Research Fund, USA• International Atomic Energy
Agency, Vienna• RHR Division of World Health Organization, Geneva, Switzerland
• University of Colorado Health
Sciences Center• The Children
• Research on Women and Child Health
• Maternal and Newborn Health Registry (MNH Registry) Dept. of OBG & Paediatrics• Helping babies breathe initiative Dept. of Paediatrics• The CLIP (Community
Level Interventions for Pre- Eclampsia) Cluster randomized controlled trial Dept. of OBG • Does Implementation of Helping Babies Breathe (HBB) save lives? Dept. of
Paediatrics• Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries
(ACT) in Belagavi District, Karnataka, India Dept. of
OBG & Paediatrics• Emergency obstetrics
20,58,000/- Twenty lakhs fifty eight
thousand
Govt. of Karnataka
Insurance companies
• Yashaswini,• Balasanjivini,
• Arogya Bhagya, • Vajapayee Arogyashree
Scheme, • Ex-servicemen Contributory Health Scheme (ECHS),
• Employe’s State Insurance (ESI), DBCS
• Psychiatry Day Care
Center KLE Dr. Prabhakar Kore
Hospital & MRC Belagavi
3,55,71,688/- Three crore fifty five lakh
seventy one thousand six hundred and eighty eight
Dr. M.V. Jali –PI ICON Clinical Research- Company
2. Protocol no: CV181169 : “A multicentre, randomised, double-blind,
active-controlled, parallel group, phase 3 trial to evaluate the safety of add-on therapy with saxagliptin and dapagliflozin added to metformin compared to add-on therapy with
saxagliptin in combination with Metformin or Dapagliflozin in combination with Metformin in subjects with Type 2 Diabetes who
have inadequate glycemic control on metformin alone”.
29,97,000/- Twenty nine lakhs ninety thousand
Glenmark - Company
3. Protocol title - C003 - adouble blind, randomized,
placebo controlled,parallel group, three arm,multicenter andmultinational pivotalstudy to assess theefficacy and safety of twodosage regimens of
crofelemer tablets in thetreatment of moderate tosevere acute waterydiarrhea in adult patients.
70,000 Seventy thousand
ZYDUS 4. Protocol no:CLR_10_22 :“Efficacy and safety ofSPIL’s Lubriprostonecapsule, 24 mcg
Lubriprostone in subjectswith chronic idiopathicconstipation : a randomized, double blind,parallel group, active andplacebo controlled,clinical endpointbioequivalence study ”.
30000/- Thirty thousand
Dr. Jayaprakash Appajigol-PI
SUN PHARMA 5. Protocol no: ZYH 1.12.001.01 PROT: “A
multicenter, prospective, randomized, open label phase IV clinical study to evaluate the safety and efficacy of saroglitzar (ZYH1) as compared to fenofibrate in patients
with dyslipidemia”.
50,000/- Fiftythousand
Dr. M.V. Jali –PI ELI LILLY 6. Protocol title: “A demonstration project to evaluate the effectiveness and acceptability of the joint diabetes evaluation
(JADE) & diabetes monitoring database(Diamond) programs in Type 2 Diabetes patients in India”.
50,000/- Fiftythousand
ELI LILLY 7.Protocol title: Protocol I4V-MC-JADX: A
randomized, double-blind, placebo-controlled, phase3 study to evaluate theefficacy and safety ofbaricitinib (LY3009104)in patients withinadequate response to
conventional disease-modifying antirheumaticdrugs with moderately toseverely activerheumatoid arthritis.
60,000/- Sixty thousand
Dr. Udapudi-PI ELI LILLY 8.Protocol title: ProtocolI4V-MC-JADZ- “Arandomized, double-blind,active-controlled, phase 3
study to evaluate theefficacy and safety ofbaricitinib (LY3009104)
in patients withmoderately to severelyactive rheumatoidarthritis who have hadlimited or no treatmentwith disease modifyingantirheumatic drugs”.
45,000/- Forty five thousand
Dr.S.Udapudi-PI ELI LILLY 9.Protocol title: I4V-MC-JADY(C): “A Phase 3,
multicenter study to evaluate the long-term safety and efficacy of baricitinib in patients with rheumatoid arthritis”.
40,000/- FortyThousand
Dr.Rajendra.Bhandankar- PIDr. Sudheer Yadwad– Sub I
ELI LILLY 10.Protocol SB2-G31-RA: “A randomized, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, pharmacokinetics
and immunogenicity of SB2 compared to remicade® in subjects with moderate to severe rheumatoid arthritis despite methotrexate therapy”.
60,000/- Sixty thousand
ELI LILLY 11.Protocol I4L-MC-ABEL: “A prospective,
randomized, open-labelcomparison of a longacting basal insulinanalog, LY2963016, tolantus® in combinationwith mealtime insulinlispro in adult patients
with type 1 diabetesmellitus: the element 3study”.
50,000/- Fifty thousand
BBIL 12. Protocol title: “Addendum to typhoid Vi polysaccharidetetanus
toxoid protein conjugate phase III clinical trial protocol entitled:A phase III, Randomized,multicentre ,controlled study to evaluate the
immunogenicity and safety of BBIL’s typhoid Vi capsular polysaccharide –tetanus toxoid protein conjugate vaccine (Typbar TCV) Vs. Referencevaccine (typbar) in healthy
subjects.”.
40,000/- Forty thousand
ZYDUS 13.Reference protocol no: CLR_13_14:Study Title:
“Pharmacodynamic efficacy and safety of Leuprolide depot 7.5 mg (SPIL) in subjects with Prostatic Adenocarcinoma”.
50,000/- Fifty thousand
BBIL 14. Protocol No: BBIL/JEV/IV/2012A: “A Phase IV Single dose, Open labeled, Comparative, Randomized
Controlled study to evaluate the Immunogenicity and Safety of BBIL’s JENVAC(Inactivated JE vaccine)Vs. Chinese SA-14-14-2(Live JE vaccine)vaccine in healthy
volunteers”.
40,000/- Forty thousand
Ranbaxy 15. Ref: Protocol :“Comparative efficacy,
safety and tolerability ofFDC of cephalexinextended release (375mg)and ClavulanatePotassium (125 mg)tablets with Cephalexinextended release (375
mg) tablets in thetreatment ofuncomplicated skin andsoft tissue infection - arandomized, double-blindstudy(study number:r2013006)”.
60,000/- Sixty thousand
Ranbaxy 16. Ref: Protocol : “Comparative efficacy, safety and tolerability of FDC of Cephalexin extended release (375mg) and Clavulanate Potassium (125 mg)
tablets with cephalexin extended release (375 mg) tablets in the treatment of upper respiratory tract infections - a randomized,
double-blind study (study number: r2013006)”.
30,000/- Thirty thousand
Dr.Jayprakash Appajigol – PI
Asahi Kasei Pharma America
Company
17.Ref:3-001 A randomized double-blind,
placebo-controlled, Phase-3 study to assess the safety and efficacy of ART-123 in subject with severe sepsis and coagulopathy.
30,000/- Thirty thousand
Dr.Rajendra.Bhandankar-PI
Sristek Company 18. Protocol title: “A multicenter, double-blind, vehicle controlled, parallel-group study comparing a generic
Diclofenac Sodium topical gel, 1% in the treatment of subjects with osteoarthritis of the knee”.
30,000/- Thirty thousand
BBIL 19. Protocol no.:BBIL/ROTA/IV/2013:
“Phase IV, multicenter,randomized, single-blind,study to evaluate theimmunogenicity, reactogenicity& safety ofthe live attenuatedrotavirus vaccine
ROTAVAC® as a 3 doseseries when administeredsimultaneously with orwithout the bufferingagent following in healthyinfants”.
45,000/- Forty five thousand
Merc Company 20. Protocol title: MK-0822-083-00: “An observational follow-up study for: a phase III randomized, placebo-controlled clinical trial to assess the safety and efficacy of Odanacatib
(MK-0822) to reduce the risk of fracture in osteoporotic postmenopausal women treated with vitamin D and calcium (protocol 018)”.
60,000/- Sixty thousand
Himalaya Drug Company,
Bengaluru
21. “A comparative clinical study to evaluate
the efficacy and safety of two cystone formulations in patients suffering from urolithiasis”.
30,000/- Thirty thousand
Progene Research Laboratories, Belagavi
22. “A Randomized,controlled, double blindstudy to evaluate theefficacy and safety ofcapsule progen inimproving parameters of
semen analysis in cases ofmale infertility due todefect in seminalparameters’.
30,000/- Thirty thousand
Medical director Medical Superintendent
Govt. of Karnataka
Balasanjeevini Vajapayee Arogya Scheme
1,29,23,090 One crore twenty nine lakhs twenty
three thousand ninety